The Future of Memory Disorders
This article was originally published in Start Up
Executive Summary
The market for products that boost memory and cognition is vast, and underserved. But until clinicians and companies define cognitive diseases and develop clinical models for them, start-ups developing memory drugs face an uncertain future. Included in this feature are profiles of Accera Inc., GBtherapeutics Ltd., Saegis Pharmaceuticals Inc. and Sention Inc.